An overview of COVID-19
暂无分享,去创建一个
Gang Wang | Min Zheng | Yu Shi | Zhi Chen | Bo Yang | G. Wang | Min Zheng | Zhi Chen | Yu Shi | Haihong Zhu | Xiao-peng Cai | Jing-wen Deng | Lin Zheng | Hai-hong Zhu | Jingwen Deng | Bo Yang | Xiaosong Cai | Lin Zheng
[1] C. Wolf,et al. Sequelae in Adults at 6 Months After COVID-19 Infection , 2021, JAMA network open.
[2] D. Buonsenso,et al. Preliminary evidence on long COVID in children , 2021, medRxiv.
[3] Guohui Fan,et al. RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2021, The Lancet.
[4] F. Journé,et al. Prevalence and 6‐month recovery of olfactory dysfunction: a multicentre study of 1363 COVID‐19 patients , 2021, Journal of internal medicine.
[5] Peter J Hellyer,et al. Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study , 2020, medRxiv.
[6] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[7] J. Cohen,et al. Reinfection with SARS-CoV-2: Implications for Vaccines , 2020, Clinical Infectious Diseases.
[8] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[9] J. Baeten,et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, Annals of Internal Medicine.
[10] M. Hellwig,et al. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin , 2020, International Journal of Antimicrobial Agents.
[11] C. Tebé,et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 , 2020, The New England journal of medicine.
[12] Amish Talwar,et al. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. , 2020, JAMA.
[13] J. Ludvigsson. Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19 , 2020, Acta paediatrica.
[14] A.I. Eltaweel,et al. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic , 2020 .
[15] E. Olsen,et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[16] Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study , 2020, medRxiv.
[17] David A. Drew,et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App , 2020, medRxiv.
[18] R. Gandhi,et al. Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2: What Goes Around May Come Back Around , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[19] W. J. Boscardin,et al. Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People , 2020, Obstetrics and gynecology.
[20] J. Balko,et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial , 2020, medRxiv.
[21] M. Marshall. The lasting misery of coronavirus long-haulers , 2020, Nature.
[22] C. Rhee,et al. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Yindalon Aphinyanaphongs,et al. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19 , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[24] T. Greenhalgh,et al. Management of post-acute covid-19 in primary care , 2020, BMJ.
[25] Chu-Chung Huang,et al. Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study , 2020, EClinicalMedicine.
[26] Jay S. Steingrub,et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[27] Manoj Sivan,et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation , 2020, Journal of medical virology.
[28] J. Dowds,et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection , 2020, medRxiv.
[29] F. Benedetti,et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors , 2020, Brain, Behavior, and Immunity.
[30] Eike Nagel,et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.
[31] J. Ramos-Rincón,et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. , 2020, Revista clinica espanola.
[32] Yawen An,et al. Psychological Distress and Its Correlates Among COVID-19 Survivors During Early Convalescence Across Age Groups , 2020, The American Journal of Geriatric Psychiatry.
[33] Angelo Carfì,et al. Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.
[34] Y. Tie,et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[35] M. Heneka,et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease , 2020, Alzheimer's Research & Therapy.
[36] Emily G McDonald,et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.
[37] A. Harky,et al. Neurological Manifestations of COVID‐19: A systematic review and current update , 2020, Acta neurologica Scandinavica.
[38] A. Topjian,et al. Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series , 2020, Journal of the Pediatric Infectious Diseases Society.
[39] E. Price-Haywood,et al. Hospitalization and Mortality among Black Patients and White Patients with Covid-19 , 2020, The New England journal of medicine.
[40] Zachary Schiffman,et al. Predicting infectious SARS-CoV-2 from diagnostic samples , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] Xingguang Li,et al. Response to comments on "Cross‐species Transmission of the Newly Identified Coronavirus 2019‐nCoV” and “Codon bias analysis may be insufficient for identifying host(s) of a novel virus” , 2020 .
[42] Kristen M J Azar,et al. Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. , 2020, Health affairs.
[43] C. Mantzoros,et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York , 2020, Metabolism.
[44] L. Kucirka,et al. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure , 2020, Annals of Internal Medicine.
[45] Angelo Mazza,et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.
[46] Hesong Zeng,et al. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging , 2020, JACC: Cardiovascular Imaging.
[47] C. Gross,et al. Racial and Ethnic Disparities in Population-Level Covid-19 Mortality , 2020, Journal of General Internal Medicine.
[48] James M. Blum,et al. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[49] H. Shan,et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase , 2020, Respiratory Research.
[50] P. Theocharis,et al. Hyperinflammatory shock in children during COVID-19 pandemic , 2020, The Lancet.
[51] Hsien-Ho Lin,et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset , 2020, JAMA internal medicine.
[52] M. Ziv,et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature , 2020, Journal of Dermatological Science.
[53] Jun Yuan,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[54] Ying Yao,et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. , 2020, Journal of the American Society of Nephrology : JASN.
[55] Anne Kimball,et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.
[56] M. Fowkes,et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) , 2020, Journal of medical virology.
[57] Yan-ling Ma,et al. Antibody Detection and Dynamic Characteristics in Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] Sheng Zhang,et al. Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56 COVID-19 Patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] Lynnette Brammer,et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[60] K. Peck,et al. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? , 2020, International Journal of Antimicrobial Agents.
[61] Yutao Guo,et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.
[62] Hongliang Li,et al. The Science Underlying COVID-19: Implications for the Cardiovascular System. , 2020, Circulation.
[63] A. Quyyumi,et al. Impact of Social Vulnerability on COVID-19 Incidence and Outcomes in the United States , 2020, medRxiv.
[64] Chaochao Tan,et al. C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early , 2020, Journal of medical virology.
[65] Mingfang Jia,et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city , 2020, European Radiology.
[66] Mario Plebani,et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis , 2020, Clinical chemistry and laboratory medicine.
[67] Cheng Wan,et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China , 2020, Kidney International.
[68] Y. Yazdanpanah,et al. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.
[69] D. Jans,et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.
[70] T. Kurita,et al. A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs , 2020, Infectious diseases.
[71] P. Thuluvath,et al. Gastrointestinal and Liver Manifestations of COVID-19 , 2020, Journal of Clinical and Experimental Hepatology.
[72] N. Lurie,et al. Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.
[73] Mohammad Madjid,et al. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.
[74] Jia-Fu Jiang,et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins , 2020, Nature.
[75] Qi Jin,et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[76] S. Inui,et al. Chest CT Findings in Cases from the Cruise Ship Diamond Princess with Coronavirus Disease (COVID-19) , 2020, Radiology. Cardiothoracic imaging.
[77] Lei Liu,et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China , 2020, Diabetes Care.
[78] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[79] R. Lu,et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.
[80] Hannah R. Meredith,et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application , 2020, Annals of Internal Medicine.
[81] Xu Liu,et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[82] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[83] Qiang Zhou,et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.
[84] J. Low,et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.
[85] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[86] Lingxi Jiang,et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests , 2020, International Journal of Infectious Diseases.
[87] Lei Liu,et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.
[88] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[89] Heshui Shi,et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet Infectious Diseases.
[90] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[91] T. Liang,et al. [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.
[92] Tao Zhang,et al. Pangolin homology associated with 2019-nCoV , 2020, bioRxiv.
[93] Linqi Zhang,et al. Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor , 2020, bioRxiv.
[94] Min Kang,et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.
[95] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[96] S. Zhang,et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.
[97] Jiyuan Zhang,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.
[98] David Cyranoski. When will the coronavirus outbreak peak? , 2020 .
[99] G. Whittaker,et al. Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses , 2020, bioRxiv.
[100] Shibo Jiang,et al. The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus , 2020, Virologica Sinica.
[101] Hongzhu Cui,et al. Structural genomics and interactomics of 2019 Wuhan novel coronavirus, 2019-nCoV, indicate evolutionary conserved functional regions of viral proteins , 2020, bioRxiv.
[102] Huixia Yang,et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Lancet.
[103] R. Wax,et al. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients , 2020, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.
[104] Y. Tong,et al. Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva , 2020, medRxiv.
[105] Huji Xu,et al. The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS , 2020, bioRxiv.
[106] Wei Liu,et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China , 2020, medRxiv.
[107] Guangdi Li,et al. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.
[108] Jie Shi,et al. 2019-nCoV epidemic: address mental health care to empower society , 2020, The Lancet.
[109] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[110] Yan Zhao,et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) , 2020, Military Medical Research.
[111] D. Musso,et al. 2019-nCoV epidemic: what about pregnancies? , 2020, The Lancet.
[112] Federico M Giorgi,et al. Genomic variance of the 2019‐nCoV coronavirus , 2020, Journal of medical virology.
[113] Q. Cui,et al. Possible Inhibitors of ACE2, the Receptor of 2019-nCoV , 2020 .
[114] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[115] Qiang Huang,et al. Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV) , 2020, bioRxiv.
[116] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[117] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[118] Christian Drosten,et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells , 2020, bioRxiv.
[119] P. Vollmar,et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.
[120] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[121] E. Holmes,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.
[122] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[123] S. Lo,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.
[124] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[125] Yonghong Xiao,et al. Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm , 2020, bioRxiv.
[126] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[127] M. Koopmans,et al. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. , 2020, The New England journal of medicine.
[128] Fei Deng,et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin , 2020, bioRxiv.
[129] Xingguang Li,et al. Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of Medical Virology.
[130] Xingguang Li,et al. Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of medical virology.
[131] Ping Chen,et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.
[132] N. Dong,et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China , 2020, bioRxiv.
[133] R. Baric,et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.
[134] K. To,et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.
[135] T. Duan,et al. Single-cell RNA expression profiling of ACE2 and AXL in the human maternal–Fetal interface , 2020 .
[136] Bo Zhong,et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak , 2020, Emerging microbes & infections.
[137] Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic , 2020 .
[138] Qun Li. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020 .
[139] Leiliang Zhang,et al. Recent Progress in Vaccine Development Against Chikungunya Virus , 2019, Front. Microbiol..
[140] Michael Proschan,et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.
[141] Jinping Chen,et al. Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica) , 2019, Viruses.
[142] R. Baric,et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase , 2019, Antiviral Research.
[143] William R. Buckingham,et al. Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. , 2018, The New England journal of medicine.
[144] Xiaotao Lu,et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.
[145] Elliot J. Lefkowitz,et al. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV) , 2017, Nucleic Acids Res..
[146] S. Yadav,et al. Post-intensive care syndrome: An overview , 2017, Journal of translational internal medicine.
[147] Z. Memish,et al. A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia , 2017, Journal of Infection.
[148] Fang Li,et al. Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.
[149] D. Falzarano,et al. SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.
[150] Ke Zhang,et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses , 2016, Scientific Reports.
[151] J. Whitehead,et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol , 2015, SpringerPlus.
[152] Jincun Zhao,et al. Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus Infection , 2015, Journal of Virology.
[153] Gary R. Whittaker,et al. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis , 2014, Virus Research.
[154] Z. Memish,et al. Respiratory Tract Samples, Viral Load, and Genome Fraction Yield in Patients With Middle East Respiratory Syndrome , 2014, The Journal of infectious diseases.
[155] Shibo Jiang,et al. Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.
[156] Yuna Sun,et al. Current progress in antiviral strategies , 2014, Trends in Pharmacological Sciences.
[157] O. Jahn,et al. TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein , 2013, Journal of Virology.
[158] C. Raker,et al. Pregnancy-induced changes in immune protection of the genital tract: defining normal. , 2013, American journal of obstetrics and gynecology.
[159] A. Osterhaus,et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.
[160] D. Corey,et al. Silencing disease genes in the laboratory and the clinic , 2012, The Journal of pathology.
[161] Mina Abbassi-Ghanavati,et al. Pregnancy and Laboratory Studies: A Reference Table for Clinicians , 2009, Obstetrics and gynecology.
[162] C. Li,et al. Host Immune Responses to SARS Coronavirus in Humans , 2009, Molecular Biology of the SARS-Coronavirus.
[163] T. Asselah,et al. Protease and polymerase inhibitors for the treatment of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[164] F. Stauffer,et al. Advances in the development of inactivated virus vaccines. , 2006, Recent patents on anti-infective drug discovery.
[165] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.
[166] D. Schaffer,et al. Antiviral RNAi therapy: emerging approaches for hitting a moving target , 2005, Gene Therapy.
[167] S. Harrison,et al. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.
[168] N. Seidah,et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.
[169] Shibo Jiang,et al. Vaccine design for severe acute respiratory syndrome coronavirus. , 2005, Viral immunology.
[170] S. Plotkin,et al. Vaccines: past, present and future , 2005, Nature Medicine.
[171] S. Pöhlmann,et al. Cellular entry of the SARS coronavirus , 2004, Trends in Microbiology.
[172] M. Iturriza-Gómara,et al. Laboratory diagnosis of SARS. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[173] Y. Guan,et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.
[174] M. Loeb,et al. Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[175] J. Dennis,et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.
[176] Christian Drosten,et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[177] J. A. Comer,et al. A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[178] Takashi Taguchi,et al. Pulmonary fibrosis: Cellular and molecular events , 2003, Pathology international.
[179] J. Bull,et al. Evolutionary Dynamics of Viral Attenuation , 2002, Journal of Virology.
[180] M. Buchmeier,et al. Coronavirus Spike Proteins in Viral Entry and Pathogenesis , 2001, Virology.
[181] A. Patick,et al. Protease Inhibitors as Antiviral Agents , 1998, Clinical Microbiology Reviews.
[182] M. Mayo,et al. Virus Taxonomy , 1995, Archives of Virology Supplement 10.
[183] J. Maniloff,et al. Virus taxonomy : eighth report of the International Committee on Taxonomy of Viruses , 2005 .